Becton, Dickinson and Company BDX
Composite 48/100; the shares have moved about 27% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 32/100 — a moderate mark against it.
Momentum ranks 64/100 — a moderate point in its favour. Income ranks 62/100 — a moderate point in its favour. Valuation ranks 54/100 — a slight point in its favour.
Balance-sheet strength ranks 32/100 — a moderate mark against it. Growth ranks 43/100 — a slight mark against it. Quality ranks 48/100 — a slight mark against it.
What the company does Becton, Dickinson and Company (BDX) designs, manufactures, and sells medical supplies, devices, and diagnostic products across Medical Essentials, Connected Care, BioPharma Systems, Interventional, and Life Sciences segments.
Key financials Revenue grew 8.2% but EPS fell -0.2%. Margins: gross 46.9%, operating 15.7%, net 4.2%. ROE 6.6%, ROA 4.3%, debt/equity 0.69, current ratio 0.86. Dividend yield 2.2%, payout 30.6%.
Stock health Sideravia scores: Overall 48.0 (Weak quality, attractively valued), Quality 48.6, Growth 46.7, Strength 32.3, Valuation 53.3, Momentum 57.5, Income 61.4. Piotroski F-Score 7/9.
Price vs fair value BDX trades at a discount of 1.30% versus the analyst mean target of 194.42. - PREVENT trial enrollment completion signals potential hernia mesh approval (Simply Wall St., Zacks) - Analysts debate whether cash-flow strength justifies broader valuation checks (Simply Wall St.) - SurgiMend relaunch may support 2027 recovery thesis (Zacks) - Barchart notes mixed analyst price targets
Looking forward Forward P/E 14.10 and PEG 0.11 suggest valuation support, while net margins at 4.2% and ROE at 6.6% indicate execution challenges. Momentum is strong (3m 32.21%, 12m 25.61%) but RSI(14) at 78.50 signals overbought conditions.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.